Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 02/14/19 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
33 | |
| 02/13/19 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 02/13/19 | S-3/A | Registration statement for specified transactions by certain issuers |
|
42 | |
| 02/13/19 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
58 | |
| 02/13/19 | 8-K | Current report filing |
|
5 | |
| 02/08/19 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
58 | |
| 02/08/19 | 8-K | Current report filing |
|
5 | |
| 02/05/19 | UPLOAD | SEC-generated letter |
|
1 | |
| 01/31/19 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
58 | |
| 01/31/19 | 8-K | Current report filing |
|
50 |
